TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Lixiana (Edoxaban)

Lixiana / Edoxaban. Used to reduce stroke risk in certain atrial fibrillation and to treat or prevent venous blood clots.

PMDAproduct-level source2025-11label updated2026-10-05site verified
リクシアナ錠15mg/30mg/60mg · 30 mg
Japanese product photo · 30 mg · 関西薬品
Main useUsed to reduce stroke risk in certain atrial fibrillation and to treat or prevent venous blood clots.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
リクシアナ錠15mg/30mg/60mg
Brand
Lixiana
Generic name
Edoxaban
Japanese generic name
エドキサバン
Chinese name
艾多沙班(依度沙班)
Marketing authorization holder
第一三共株式会社
Strengths
15 mg / 30 mg / 60 mg
Dosage form
tablet
Therapeutic area
Cardiovascular
Regulatory status
Rx
Label updated
2025-11
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Lixiana is a direct oral factor-Xa anticoagulant. Dose depends on indication, weight, renal function and other factors.

Read source section ↗
02

Mechanism of action

Directly inhibits factor Xa and reduces thrombin generation; bleeding risk must be balanced against clot prevention.

Read source section ↗
03

Japanese indications & eligibility

Japanese uses cover selected AF stroke prevention, VTE treatment/prevention, CTEPH and specified orthopedic procedures.

Read source section ↗
04

Administration & dose differences

Common adult doses are 30 mg daily at ≤60 kg and 60 mg at >60 kg, with renal/drug adjustments; 15 mg has restricted elderly AF criteria.

Read source section ↗
05

Adverse effects & key risks

Major risk is bleeding, including intracranial/GI bleeding. Do not stop treatment without a clinical plan.

Read source section ↗
06

Contraindications & special populations

Contraindications include active significant bleeding and specified renal/hepatic conditions; renal thresholds differ by indication.

Read source section ↗
07

Drug interactions

Review other antithrombotics, NSAIDs and P-gp inhibitors; procedures and switching require a plan.

Read source section ↗
08

Assessment & monitoring

Monitor renal/hepatic function, hemoglobin and bleeding; routine INR is not a dose-titration measure for edoxaban.

Read source section ↗
09

Storage & handling

Store at room temperature. The photo shows the Japanese 30 mg box.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.